• Navidea Biopharmaceuticals Inc. (formerly Neoprobe Corp.), of Dublin, Ohio, said data from its Phase III study of Lymphoseek (99m-Tc-Tilmanocept) in oral and squamous cell cancers suggested the radiopharmaceutical improves identification of primary draining nodes to properly stage patients with head and neck squamous cell cancers using sentinel lymph node mapping.